Analysis of disease-free survival (DFS) in breast cancer patients with and without the CD44+/CD24- phenotype. A. All patients; B. Patients with invasive ductal carcinoma; C. Progesterone receptor (PR) negative patients; D. PR positive patients; E. Estrogen receptor (ER) negative patients; F. ER positive patients; G. Her2 negative patients; H. Her2 positive patients; I. Patients with basal-like features; J. Patients not receiving postoperative immunotherapy; K. Patients receiving postoperative immunotherapy.